Mitochondrial DNA biomarkers to assess responses to changes in personal environmental exposures in pediatric urban asthma
Project Number7R21ES029607-02
Former Number1R21ES029607-01A1
Contact PI/Project LeaderMILLER, RACHEL L
Awardee OrganizationICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Description
Abstract Text
Urban children are exposed disproportionately to air pollution and indoor allergens that trigger asthma
symptoms. To better address this public health problem, we propose to leverage two established and
comparable urban cohorts: 1) randomized controlled trial (RCT) “Environmental Control as Add-on Therapy in
Childhood Asthma” (ECATCh) that is determining the efficacy of adding individually tailored, multi-faceted
home environmental control strategy (ECS) to titration of controller medication (TCM) over 6 months among
predominantly African American children with persistent asthma, and 2) observational case control “Traffic
Associated Air Pollution Asthma Study” (TAPAS) over 6 months among African American and Dominican
children with and without asthma. We propose to determine the contribution of novel mitochondrial (mt) DNA
biomarkers that capture responses to multiple environmental stressors, and are more sensitive to the dynamics
of dysregulation, on lung function and airway inflammation. Our objective is to elucidate the dynamic interplay
between reductions in multiple inflammatory urban exposures, attributable changes in mtDNA content
and methylation of mitochondrial regulatory genes, and improvements in asthma outcomes over time. In two
well-defined cohorts representing minority urban pediatric populations, we hypothesize that reversal of
mitochondrial damage following personalized ECS and other time-related changes in multiple
environmental exposures is associated with improved lung function and airway inflammation. We
predict that intermediate mitochondrial biomarkers following changes in diverse personal environmental
exposures may link directly to clinical outcomes. Using two repeat measures of buccal mtDNA content and
buccal genomic DNA methylation of displacement loop and other regions important to mitochondrial function,
we propose to: 1) Determine differences in mitochondrial biomarkers among ECATCh asthma cases, TAPAS
asthma cases, and TAPAS nonasthmatic controls, and the associations of mitochondrial biomarkers with
exhaled nitric oxide (eNO) and lung function within asthma cases, measured concurrently and as changes over
6 months. 2) Determine associations of repeat mitochondrial biomarkers with repeat residential measures of
fine particulate matter (PM)2.5 and other asthmogenic exposures, and 3) Explore whether 6-month treatment
with personalized multi-faceted ECS plus TCM vs TCM alone (i.e. ECATCh RCT group assignment) of
persistent asthmatics changes mitochondrial biomarkers. Significant associations from these two cohorts will
be replicated in our single-faceted environmental intervention RCT “Mouse Allergen and Asthma Intervention
Trial” (MAAIT). This proposal intends to capture the pivotal role of novel mitochondrial biomarkers in measuring
the dynamic biological responses following induction and remediation of oxidative damage, triggered by a
child’s changing personal environment. These results could direct more effective personalized biomarker-
guided therapy for urban children with persistent asthma.
Public Health Relevance Statement
We propose to leverage two established and comparable urban cohorts of children with and without
asthma each followed over 6 months to elucidate how urban exposures worsen lung function and increase
airway inflammation. We propose to determine the contribution of novel mitochondrial (mt) DNA biomarkers
that capture responses to multiple environmental stressors, and are more sensitive to the dynamics of
dysregulation. Our premise is that we can elucidate the dynamic interplay between reductions in multiple
inflammatory urban exposures, attributable changes in mtDNA content and methylation of mitochondrial
regulatory genes, and improvements in asthma outcomes over time to optimize strategies to reduce risk and
improve therapy for children with asthma.
National Institute of Environmental Health Sciences
CFDA Code
113
DUNS Number
078861598
UEI
C8H9CNG1VBD9
Project Start Date
01-September-2019
Project End Date
31-August-2021
Budget Start Date
30-January-2020
Budget End Date
31-August-2020
Project Funding Information for 2019
Total Funding
$247,888
Direct Costs
$164,124
Indirect Costs
$83,764
Year
Funding IC
FY Total Cost by IC
2019
National Institute of Environmental Health Sciences
$247,888
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7R21ES029607-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R21ES029607-02
Patents
No Patents information available for 7R21ES029607-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R21ES029607-02
Clinical Studies
No Clinical Studies information available for 7R21ES029607-02
News and More
Related News Releases
No news release information available for 7R21ES029607-02
History
No Historical information available for 7R21ES029607-02
Similar Projects
No Similar Projects information available for 7R21ES029607-02